story of the week
Overall Survival With Palbociclib and Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
Clin. Cancer Res 2022 Aug 15;28(16)3433-3442, M Cristofanilli, HS Rugo, SA Im, DJ Slamon, N Harbeck, I Bondarenko, N Masuda, M Colleoni, A DeMichele, S Loi, H Iwata, B O'Leary, F André, S Loibl, E Bananis, Y Liu, X Huang, S Kim, MJ Lechuga Frean, NC TurnerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.